Thioridazine improves affective symptoms in schizophrenic patients

Area of Science:

• Psychiatry
• Clinical Pharmacology
• Neuroscience

Background:

• Schizophrenia is a chronic mental disorder requiring long-term treatment.
• Antipsychotic medications are the cornerstone of schizophrenia management.
• Evaluating the comparative efficacy and side effect profiles of different antipsychotics is crucial for optimizing patient care.

Purpose of the Study:

• To compare the efficacy of thioridazine, molindone, and haloperidol in treating schizophrenia.
• To assess the impact of these antipsychotics on psychiatric symptoms and weight changes.

Main Methods:

• A randomized controlled trial involving schizophrenic patients aged 18-63 years.
• Patients were withdrawn from antipsychotics for at least one week before treatment.
• Participants received thioridazine (n=13), molindone (n=10), or haloperidol (n=12) for a minimum of six weeks.

Main Results:

• Thioridazine treatment resulted in significant improvements in Brief Psychiatric Rating Scale (BPRS) and Hamilton Rating Scale for Depression (HAM-D) scores compared to molindone and haloperidol.
• Improvements were most notable in anxiety and depression symptoms.
• Molindone treatment was associated with an average weight loss of 5 pounds, while thioridazine treatment led to an average weight gain of 6 pounds. Haloperidol showed no significant weight changes.

Conclusions:

• Thioridazine demonstrates superior efficacy in alleviating core schizophrenia symptoms, especially anxiety and depression, over a 6-week period.
• The choice of antipsychotic impacts weight, with molindone causing weight loss and thioridazine causing weight gain.
• Further research is warranted to explore long-term efficacy and side effect profiles for these agents in schizophrenia treatment.